2,3-dinor, 6-keto-PGF1alpha

2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Body Weight D001835 333 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Tibial Fractures D013978 4 associated lipids
Thrombosis D013927 49 associated lipids
Endometriosis D004715 29 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Per page 10 20 50 | Total 25

NCBI Entrez Crosslinks

All references with 2,3-dinor, 6-keto-PGF1alpha

Download all related citations
Per page 10 20 50 100 | Total 191
Authors Title Published Journal PubMed Link
Numminen H et al. The effect of acute ingestion of a large dose of alcohol on the hemostatic system and its circadian variation. 2000 Stroke pmid:10835443
Delemarre FM et al. Urinary prostaglandin excretion in pregnancy: the effect of dietary sodium restriction. 2000 Prostaglandins Leukot. Essent. Fatty Acids pmid:11049696
Brown NJ et al. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. 2000 Circulation pmid:11056091
Tsikas D et al. Solid- and liquid-phase extraction for the gas chromatographic-tandem mass spectrometric quantification of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-oxo-prostaglandin F1 alpha in human urine. 2000 J Chromatogr A pmid:10941682
McAdam BF et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:9874808
Morrow JD et al. Increased formation of thromboxane in vivo in humans with mastocytosis. 1999 J. Invest. Dermatol. pmid:10417625
Catella-Lawson F et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. 1999 J. Pharmacol. Exp. Ther. pmid:10215647
Barden AE et al. Does a predisposition to the metabolic syndrome sensitize women to develop pre-eclampsia? 1999 J. Hypertens. pmid:10489109
Mills JL et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. 1999 JAMA pmid:10432033
Arvola P et al. Exercise enhances vasorelaxation in experimental obesity associated hypertension. 1999 Cardiovasc. Res. pmid:10615427